Strides Pharma Q1 Results: US sales improve 7%, gross margins expand

Strides Pharma’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 14.7% from the year-ago quarter to ₹217.9 crore, while margins expanded by 150 basis points to 19.5% from 18% last year.

Leave a Reply

Your email address will not be published. Required fields are marked *